ClinicalTrials.gg
CompletedNCT02988973Updated Oct 31, 2024

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

A Phase 3 interventional study of roxadustat and DA in Chronic Kidney Disease, sponsored by Astellas Pharma Inc. Completed at 66 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing roxadustat in Renal Insufficiency, Chronic — none open to participants now, 1 under way, 1 of them phase 3. roxadustat · Renal Insufficiency, Chronic.

Enrollment
7th of 19
334 · median 161
Started
2017
with 1 other
Phase 3
12 of 19
none open now
Registered
14th of 19
by date
Lead sponsor
2 of 19
Astellas Pharma Inc

Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 14th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 19 studies testing roxadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing roxadustat in Renal Insufficiency, Chronic as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

Read the detailed description

This study consists of the following three cohorts. Cohort 1; subjects converted from rHuEPO or DA to ASP1517, Cohort 2; subjects converted from rHuEPO or DA to DA, Cohort 3; subjects converted from epoetin beta pegol (CERA) to ASP1517. In Cohort 1 and 3, ASP1517 will be administered orally for 52 weeks. In Cohort 2, DA will be administered subcutaneously for 24 weeks.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Roxadustat
  • Anemia
  • Non-dialysis chronic kidney disease
  • ASP1517
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who were diagnosed with non-dialysis Chronic Kidney Disease and who are considered not to require renal replacement therapy during the study period
  • Subjects with renal anemia who have been receiving erythropoiesis stimulating agent (ESA) by subcutaneous injection and whose values are considered stable.
  • Mean of the subject's two most recent Hb values before randomization during the Screening Period must be ≥10.0 g/dL and ≤12.0 g/dL
  • Either transferrin saturation ≥ 20% or serum ferritin ≥ 100 ng/mL
  • Female subject must either:

Be of non-:

  • , or
  • documented surgically sterile Or, if of childbearing potential,
  • Agree not to try to become pregnant during the study and for 28 days after the final study drug administration
  • And have a negative urine pregnancy test at pre-screening
  • And, if heterosexually active, agree to consistently use two forms of highly effective * (at least one of which must be a barrier method) starting at pre-screening and throughout the study period and continued for 28 days after the final study drug administration.

    • Female subject must agree not to breastfeed starting at pre-screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Female subject must not donate ova starting at pre-screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and continue throughout the study period, and for 12 weeks after the final study drug administration
    • Male subject must not donate sperm starting at pre-screening and throughout the study period and, for 12 weeks after the final study drug administration

Exclusion criteria

Exclusion Criteria:

  • Concurrent retinal neovascular lesion untreated or macular edema untreated, and patients with any condition that significantly compromises the ability to visualize the retina
  • Concurrent disease with inflammation that could impact erythropoiesis
  • History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastro-paresis
  • Uncontrolled hypertension
  • Concurrent congestive heart failure ( Class III or higher)
  • History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the pre-screening assessment
  • Positive for surface antigen (HBsAg) or anti- virus (HCV) antibody at the pre-screening assessment, or positive for (HIV) in a past test
  • Concurrent other form of anemia than renal anemia
  • History of pure red cell aplasia
  • Having received treatment with protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the pre-screening assessment
  • (AST), Alanine Aminotransferase (ALT), or total that is greater than the criteria, or previous or concurrent another serious liver disease at pre-screening assessment
  • Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
  • Having undergone red blood transfusion and/or a surgical procedure consider to promote anemia and/or ophthalmological surgery within 4 weeks before the pre-screening assessment
  • Having undergone a kidney transplantation
  • History of serious drug allergy including anaphylactic shock
  • Having a previous history of treatment with ASP1517 or participation in this study
  • Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before acquisition
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
334 participants (actual)

Study arms

  • Experimental
    rHuEPO or DA to ASP1517

    Participants will receive roxadustat according to the prior randomization treatment, with starting doses of 70mg thrice weekly (TIW) to participants on \<4500 IU/week of rHuEPO or \<20 microgram (μg)/week of darbepoetin alfa (DA) and 100mg TIW to participants on ≥4500 IU/week rHuEPO or ≥ 20 μg/week DA. Participants roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.

    Drug: roxadustat

  • Experimental
    rHuEPO or DA to DA

    Participants will receive DA according to the prior randomization treatment, with starting doses of 15 μg/2weeks to participants on ≤ 1500 IU/week of rHuEPO or \<11.25 microgram (μg)/week of DA, 30μg/2weeks to participants on \>1500 to \<6000 IU/week of rHuEPO or ≥ 11.25 to \< 22.5 μg/week of DA, 60μg/2weeks to participants on ≥ 6000 IU/week of rHuEPO or ≥ 22.5 to \< 37.5 μg/week of DA, 90μg/2weeks to participants on ≥ 37.5 to \< 52.5 μg/week of DA, 120μg/2weeks to participants on ≥ 52.5 to \< 75 μg/week of DA, 180μg/2weeks to participants on ≥ 75 μg/week of DA. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 15, 30, 60, 90, 120, and 180 μg.

    Drug: DA

  • Experimental
    Epoetin beta pegol to ASP1517

    Participants will receive roxadustat according to the prior registration treatment, with starting doses of 70mg thrice weekly (TIW) to participants on ≤100 μg/week of Epoetin beta pegol and 100mg TIW to participants on \>100 μg/week of Epoetin beta pegol. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.

    Drug: roxadustat

Interventions

  • Oral administration

    Also known as: ASP1517

  • DrugDA

    Subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Change from baseline in the average Hemoglobin (Hb)

    Time frame: Baseline and Weeks 18 to 24

Secondary outcomes

  1. Average Hb from Week 18 to Week 24

    Time frame: Up to Week 24

  2. Number of Participants Who Achieved the Average Hb level of 10.0 to 12.0 g/dL For Weeks 18 to 24

    Time frame: Weeks 18 to 24

  3. Number of participants who achieve the target Hb level at each week

    Time frame: Up to Week 24

  4. Change from baseline in Hb to each post-dosing time point

    Time frame: Baseline and Up to Week 52

  5. Proportion of time points that achieve the target Hb level from Weeks 18 to 24

    Time frame: Up to Week 24

  6. Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment

    Time frame: Up to Week 4

  7. Quality of life assessed by SF-36

    SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey

    Time frame: Up to Week 52

  8. Quality of life assessed by EQ-5D-5L

    EQ-5D: EuroQol 5 Dimension 5 Levels

    Time frame: Up to Week 52

  9. Quality of life assessed by WPAI:ANS

    WPAI:ANS: Work Productivity and Activity Impairment Questionnaire: Anaemic Symptoms

    Time frame: Up to Week 52

  10. Quality of life assessed by FACT-An

    FACT-An: Functional Assessment of Cancer Therapy-Anemia

    Time frame: Up to Week 52

  11. Average Hb from weeks 44 to 52

    Time frame: Up to Week 52

  12. Change from baseline in the average Hb from weeks 44 to 52

    Time frame: Baseline and Up to Week 52

  13. Number of Participants Who Achieved the Average Hb level of 10.0 to 12.0 g/dL For Weeks 44 to 52

    Time frame: Weeks 44 to 52

  14. Number of participants who achieve the target Hb level at each week

    Time frame: Up to Week 52

  15. Proportion of time points that achieve the target Hb level from Weeks 44 to 52

    Time frame: Up to Week 52

  16. Average Hematocrit Level

    Time frame: Up to Week 52

  17. Average Reticulocyte Level

    Time frame: Up to Week 52

  18. Average Ferrum Level

    Time frame: Up to Week 52

  19. Average Ferritin Level

    Time frame: Up to Week 52

  20. Average Transferrin Level

    Time frame: Up to Week 52

  21. Average Total Iron Binding Capacity Level

    Time frame: Up to Week 52

  22. Average Soluble Transferrin Receptor Level

    Time frame: Up to Week 52

  23. Average Soluble Transferrin Level

    Time frame: Up to Week 52

  24. Average Reticulocyte Hemoglobin Content Level

    Time frame: Up to Week 52

  25. Number of Occurence of Hospitalizations

    Time frame: Up to Week 52

  26. Duration of Hospitalization

    Time frame: Up to week 52

  27. Number of participants with abnormal Vital signs and/or adverse events related to treatment

    Time frame: Up to Week 52

  28. Safety assessed by body weight

    Time frame: Up to Week 52

  29. Safety assessed by incidence of adverse events

    Time frame: Up to Week 52

  30. Safety assessed by standard 12-lead electrocardiogram

    Time frame: Up to Week 52

  31. Safety assessed by ophthalmological examination: Fundoscopy

    Time frame: Up to Week 24

  32. Safety assessed by ophthalmological examination: optical coherence tomography

    Time frame: Up to Week 24

  33. Safety assessed by ophthalmological examination: visual acuity

    Time frame: Up to Week 24

  34. Number of participants with abnormal Laboratory values and/or adverse events related to treatment

    Time frame: Up to Week 52

  35. Plasma concentration of unchanged ASP1517

    Time frame: Up to Week 24

07

Study locations

66 sites
  • Site JP00009
    Kasugai, Aichi, Japan
  • Site JP00030
    Nagoya, Aichi, Japan
  • Site JP00051
    Nagoya, Aichi, Japan
  • Site JP00021
    Toyohashi, Aichi, Japan
  • Site JP00003
    Sakura, Chiba, Japan
  • Site JP00038
    Matsuyama, Ehime, Japan
  • Site JP00044
    Matsuyama, Ehime, Japan
  • Site JP00008
    Kitakyusyu, Fukuoka, Japan
  • Site JP00013
    Kitakyusyu, Fukuoka, Japan
  • Site JP00040
    Kitakyusyu, Fukuoka, Japan
  • Site JP00057
    Kitakyusyu, Fukuoka, Japan
  • Site JP00042
    Kurume, Fukuoka, Japan
  • Site JP00041
    Tajimi, Gifu, Japan
  • Site JP00002
    Maebashi, Gunma, Japan
  • Site JP00037
    Hatsukaichi, Hiroshima, Japan
  • Site JP00050
    Kure, Hiroshima, Japan
  • Site JP00049
    Aasahikawa, Hokkaido, Japan
  • Site JP00007
    Sapporo, Hokkaido, Japan
  • Site JP00064
    Sapporo, Hokkaido, Japan
  • Site JP00022
    Amagasaki, Hyogo, Japan
  • Site JP00066
    Nishinomiya, Hyogo, Japan
  • Site JP00052
    Hitachi, Ibaraki, Japan
  • Site JP00017
    Kasama, Ibaraki, Japan
  • Site JP00028
    Koga, Ibaraki, Japan
  • Site JP00053
    Naka, Ibaraki, Japan
  • Site JP00023
    Sashima-gun, Ibaraki, Japan
  • Site JP00019
    Toride, Ibaraki, Japan
  • Site JP00046
    Tsuchiura, Ibaraki, Japan
  • Site JP00035
    Kanazawa, Ishikawa, Japan
  • Site JP00031
    Morioka, Iwate, Japan
  • Site JP00047
    Fujisawa, Kanagawa, Japan
  • Site JP00001
    Kamakura, Kanagawa, Japan
  • Site JP00016
    Yokohama, Kanagawa, Japan
  • Site JP00048
    Yokohama, Kanagawa, Japan
  • Site JP00012
    Sendai, Miyagi, Japan
  • Site JP00036
    Ueda, Nagano, Japan
  • Site JP00059
    Higashiosaka, Osaka, Japan
  • Site JP00005
    Izumisano, Osaka, Japan
  • Site JP00011
    Sakai, Osaka, Japan
  • Site JP00069
    Yao, Osaka, Japan
  • Site JP00029
    Ageo, Saitama, Japan
  • Site JP00004
    Koshigaya, Saitama, Japan
  • Site JP00020
    Koshigaya, Saitama, Japan
  • Site JP00025
    Adachi-ku, Tokyo, Japan
  • Site JP00043
    Bunkyo-ku, Tokyo, Japan
  • Site JP00063
    Chiyoda-ku, Tokyo, Japan
  • Site JP00067
    Hino, Tokyo, Japan
  • Site JP00015
    Koto-ku, Tokyo, Japan
  • Site JP00024
    Minato-ku, Tokyo, Japan
  • Site JP00006
    Musashino, Tokyo, Japan
  • Site JP00060
    Ota-ku, Tokyo, Japan
  • Site JP00062
    Tachikawa, Tokyo, Japan
  • Site JP00014
    Fukui, Japan
  • Site JP00033
    Fukuoka, Japan
  • Site JP00065
    Fukuoka, Japan
  • Site JP00032
    Hiroshima, Japan
  • Site JP00039
    Hiroshima, Japan
  • Site JP00045
    Kyoto, Japan
  • Site JP00018
    Nagano, Japan
  • Site JP00068
    Nagano, Japan
  • Site JP00026
    Niigata, Japan
  • Site JP00034
    Oita, Japan
  • Site JP00055
    Okayama, Japan
  • Site JP00056
    Osaka, Japan
  • Site JP00061
    Osaka, Japan
  • Site JP00010
    Toyama, Japan
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Akizawa T, Tanaka-Amino K, Otsuka T, Yamaguchi Y. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients. Am J Nephrol. 2021;52(9):702-713. doi: 10.1159/000519043. Epub 2021 Oct 8. PubMed 34628408 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2019, 32 months.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 32 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2016
First posted
Dec 12, 2016
StartActual
Jan 12, 2017
Primary completionActual
Sep 13, 2019
CompletionActual
Mar 26, 2020
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02988973
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Dec 12, 2016
Start date
Jan 12, 2017
Primary completion
Sep 13, 2019
Completion
Mar 26, 2020
Last update
Oct 31, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion